This increasing knowledge will open the door to developing effective anticancer combination therapies that can reverse CCL20-mediated chemotaxis of immunosuppressive cells including neutrophils, macrophages, Tregs, and MDSCs while enhancing immune-mediated destruction of cancer. This evidence concerns the gene CCL20 and cancer.